IMV (NASDAQ:IMV) provides updates on the development of DPX-COVID-19, a vaccine candidate against coronavirus.
The Company has used sequences of the virus and
immunoinformatics to predict and identify several hundred epitopes, of
which 23 were selected for their biological relevance and potential to
generate neutralizing antibodies against SARS-CoV-2.
Based on this analysis, IMV has begun
manufacturing peptide candidates targeting these epitopes and
preparation for the cGMP batch required to support a clinical study in
humans.
Preclinical assays in animal models are also
planned in April through May of this year to validate the safety and
potency of the vaccine candidate before initiating the human clinical
study.
The design of a Phase 1 clinical study in 48 healthy subjects has been completed.
IMV has initiated discussions with Health Canada
in preparation for a Clinical Trial Application. A meeting is scheduled
in the week of April 20, with the goal to initiate the clinical study in
the summer of 2020.
Shares are up 28% premarket.
https://seekingalpha.com/news/3556188-imv-updates-development-of-dpx-covidminus-19-vaccine-shares-up-28-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.